EDITORIAL

The value of real-world data to inform cancer research and care
Well-designed real-world observational studies are hypothesis-generating and impact therapeutic decisions
ESMO ASIA CONGRESS 2023

Real-world data give insights into toxicities associated with immunotherapy
Novel approaches including the use of a JAK-STAT inhibitor, a nomogram and assessment of eosinophil proportions are presented for improving the management of immune-related adverse events
Additional data confirm the promise of combination therapies for EGFR-mutated NSCLC
Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings
New models show promise for predicting response to treatment in HER2-positive breast cancer
Personalisation of treatment could be a step closer by integrating several cancer characteristics, but consolidation of data from these tools is needed before their use in clinical practice
NEWS

New Pan-Asian-adapted recommendations on gastric cancer and early breast cancer presented by ESMO
The two Pan-Asian Guideline Adaptations of parental ESMO Clinical Practice Guidelines reflect the younger age of disease occurrence and lack of some treatment data in Asia
NASOPHARYNGEAL CANCER

Targeted therapy shows early promise in EBV-positive nasopharyngeal carcinoma
In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy
Three decades of progress in nasopharyngeal cancer
Tailored management for high-risk locoregional disease, together with more effective immunotherapy combinations are key areas of exploration in nasopharyngeal cancer, according to 2023 ESMO Lifetime Achievement awardee Prof. Anthony Chan
OTHER NEWS

Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
Dostarlimab shows preliminary but durable activity across multiple cancers
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Adding atezolizumab to bevacizumab and chemotherapy improves outcomes in metastatic cervical cancer
Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients